Capecitabine

Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.

🧴 Clinical Application

Take orally twice daily (morning and evening), approximately 12 hours apart, strictly WITHIN 30 MINUTES AFTER A MEAL with a full glass of water. Swallow tablets whole; do not crush or split. Standard regimen is 1250 mg/m² twice daily for 14 days, followed by a 7-day rest period (21-day cycle).

⚠️ Side Effects

Common: Hand-foot syndrome (palmar-plantar erythrodysesthesia: numbness, erythema, swelling, blistering of palms and soles in >50%), diarrhea, nausea, vomiting, fatigue, stomatitis. Rare/Severe: Severe hyperbilirubinemia, cardiotoxicity (angina/arrhythmias), lethal toxicity in DPD-deficient patients, and Stevens-Johnson syndrome.

🛡️ Safety Warnings

Black Box Warning: Clinically significant interaction with warfarin; capecitabine markedly inhibits CYP2C9, causing dangerous increases in INR and fatal bleeding (monitor INR frequently). Black Box Warning: DPD deficiency carries fatal toxicity risk. Interrupt therapy immediately at grade 2 hand-foot syndrome or diarrhea until resolution. Contraindicated in severe renal impairment (CrCl < 30 mL/min).